Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 17/20 | 0.66 |
| ▸ | MMP1 | P03956 | 16/20 | 0.66 |
| ▸ | MMP2 | P08253 | 8/20 | 0.66 |
| ▸ | MMP9 | P14780 | 5/20 | 0.66 |
| ▸ | MMP3 | P08254 | 4/20 | 0.66 |
| ▸ | MMP8 | P22894 | 3/20 | 0.66 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.54 |
| ▸ | MMP14 | P50281 | 3/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | MMP7 | P09237 | 1/20 | 0.54 |
| ▸ | MMP10 | P09238 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6995105 | 0.90 | MMP1 (0.57) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL6994365 | 0.89 | MMP1 (0.69) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL6994368 | 0.89 | MMP1 (0.69) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL7000964 | 0.88 | MMP13 (0.53) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL7000967 | 0.88 | MMP13 (0.53) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL7002033 | 0.88 | MMP1 (0.55) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL6994480 | 0.86 | MMP13 (0.49) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL6994478 | 0.86 | MMP13 (0.49) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL7137882 | 0.85 | MMP13 (0.54) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL7139217 | 0.84 | MMP13 (0.53) | MMP13MMP1MMP2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1070069-B1 | BICYCLIC HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2003-07-16 | — | — | EP | claimed |
| EP-1070069-B1 | BICYCLIC HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6288246-B1 | REACTION OF HYDROXYLAMINE WITH ALKYLSILYL HALIDE, HYDROLYSIS WITH ACID | PFIZER INC | 2001-09-11 | — | — | US | disclosed |
| EP-1070069-A1 | BICYCLIC HYDROXAMIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2001-01-24 | — | — | EP | disclosed |
| US-6110964-A | FOR TREATING ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, EMPHYSEMA, ACUTE RESPIRATORY DISTRESS SYNDROME, ASTHMA CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ALZHEIMER'S DISEASE, ORGAN TRANSPLANT TOXICITY, CACHEXIA, CANCER | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
| WO-1999052910-A1 | BICYCLIC HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0949244-A2 | Process for preparing hydroxamic acids | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |